Evidence supporting the use of: Cannabigerol
For the health condition: Autoimmune Disorders

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis sativa plant. Its use for autoimmune disorders is supported by early-stage scientific research, primarily preclinical studies. CBG interacts with the endocannabinoid system, particularly the CB1 and CB2 receptors, and has demonstrated anti-inflammatory and immunomodulatory properties in animal models and in vitro studies. For instance, studies have shown that CBG can reduce inflammation in models of inflammatory bowel disease (IBD) and may modulate immune cell function by inhibiting the release of certain pro-inflammatory cytokines. These findings suggest potential therapeutic benefits for conditions characterized by immune dysregulation, such as autoimmune disorders. However, there is a lack of robust clinical evidence in humans. No large-scale, placebo-controlled clinical trials have been conducted to validate CBG’s efficacy or safety for treating autoimmune diseases. The current evidence base is limited to laboratory and animal research, which does not always translate to similar results in humans. Additionally, there is little historical or traditional use of CBG specifically for autoimmune conditions, as CBG was only recently isolated and studied in detail. In summary, while early scientific findings indicate potential, high-quality human data is lacking, and the evidence to support CBG’s use in autoimmune disorders is preliminary.

More about cannabigerol
More about Autoimmune Disorders

Products containing cannabigerol

We currently have no products on Vitabase that contain this ingredient.